Show simple item record

dc.contributor.authorSareen, N
dc.contributor.authorSequiera, GL
dc.contributor.authorChaudhary, R
dc.contributor.authorAbu-El-Rub, E
dc.contributor.authorChowdhury, SR
dc.contributor.authorSharma, Vikram
dc.contributor.authorSurendran, A
dc.contributor.authorMoudgil, M
dc.contributor.authorFernyhough, P
dc.contributor.authorRavandi, A
dc.contributor.authorDhingra, S
dc.date.accessioned2018-05-10T10:58:57Z
dc.date.issued2018-05-02
dc.identifier.issn1757-6512
dc.identifier.issn1757-6512
dc.identifier.other121
dc.identifier.urihttp://hdl.handle.net/10026.1/11487
dc.descriptionNo embargo required.
dc.description.abstract

BACKGROUND: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy. Presently, the most commonly used passages for transplantation include passages (P)3-7. Therefore, in this study we included clinically relevant passages, i.e., P3, P5, and P7, for evaluation. METHODS: The immunoprivilege of MSCs was assessed with the mixed leukocyte reaction assay, where rat MSCs were cocultured with peripheral blood leukocytes for 72 h. Leukocyte-mediated cytotoxicity, apoptosis (Bax/Bcl-xl ratio), leukocyte proliferation, and alterations in cellular bioenergetics in MSCs were assessed after the coculture. Furthermore, the expression of various oxidized phospholipids (oxidized phosphatidylcholine (ox-PC)) was analyzed in MSCs using a lipidomic platform. To determine if the ox-PCs were acting in tandem with downstream intracellular protein alterations, we performed proteome analysis using a liquid chromatography/mass spectrometry (LC/MS) proteomic platform. RESULTS: Our data demonstrate that MSCs were immunoprivileged at all three passages since coculture with leukocytes did not affect the survival of MSCs at P3, P5, and P7. We also found that, with an increase in the passage number of MSCs, leukocytes did not cause any significant effect on cellular bioenergetics (basal respiration rate, spare respiratory capacity, maximal respiration, and coupling efficiency). Interestingly, in our omics data, we detected alterations in some of the ox-PCs and proteins in MSCs at different passages; however, these changes were not significant enough to affect their immunoprivilege. CONCLUSIONS: The outcome of this study demonstrates that an increase in passage number (from P3 to P7) in the cell culture does not have any significant effect on the immunoprivilege of MSCs.

dc.format.extent121-
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherSpringer Science and Business Media LLC
dc.subjectApoptosis
dc.subjectBioenergetics
dc.subjectImmunoprivilege
dc.subjectLipidomics
dc.subjectMesenchymal stem cells
dc.subjectPassage
dc.subjectProteomics
dc.subjectAnimals
dc.subjectApoptosis
dc.subjectCell Differentiation
dc.subjectCell Proliferation
dc.subjectHumans
dc.subjectMale
dc.subjectMesenchymal Stem Cells
dc.subjectProteomics
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.titleEarly passaging of mesenchymal stem cells does not instigate significant modifications in their immunological behavior
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29720263
plymouth.issue1
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalStem Cells Research and Therapy
dc.identifier.doi10.1186/s13287-018-0867-4
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Biomedical Sciences
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2018-05-02
dc.rights.embargodate2019-11-23
dc.identifier.eissn1757-6512
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1186/s13287-018-0867-4
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-05-02
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV